创新药“急刹”，资金逆市扫货，创新药“新势力”港股通创新药ETF（520880）近10日吸金超7亿元

Group 1 - The core viewpoint of the article highlights a significant pullback in the innovative drug sector, attributed to disappointing mid-term earnings and potential tariffs on imported drugs proposed by Trump, which have created market uncertainty [1] - Institutions believe the recent adjustment is a technical correction following a rapid increase, and they maintain a long-term positive outlook on the innovative drug sector due to domestic policy support and overseas value recognition [1][2] - The National Healthcare Security Administration's confirmation of a "first launch price mechanism" for new drugs is expected to provide higher pricing freedom and efficiency for high-quality innovative drugs, leading to faster cash flow returns for developers [1] Group 2 - Despite the recent market pullback, there has been a trend of increased investment, with the Hong Kong Stock Connect innovative drug ETF (520880) seeing a net inflow of 47.1 million yuan over four days and 715 million yuan over ten days [2] - The Hong Kong Stock Connect innovative drug ETF (520880) passively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, focusing on the innovative drug industry chain with a high concentration of leading stocks [4] - The Hang Seng Hong Kong Stock Connect Innovative Drug Select Index has outperformed other indices significantly, with a year-to-date increase of 101.58%, surpassing the Hang Seng Index and Hang Seng Technology Index by 78.08 and 79.53 percentage points, respectively [6]